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Characterization of human infiltrating γδ T cells 
in prostate cancer. 
Preface 
Tumor-infiltrating lymphocytes are key mediators of tumor 
immune surveillance and are important prognostic 
indicators in cancer progression. Among the various 
lymphocyte subsets implicated in protection against cancer 
are γδ T lymphocytes, which can kill tumor cells and secrete 
potent antitumor cytokines. The role of γδT cells is 
controversial. They are potent mediators of antitumor 
cytotoxicity and have shown promising efficacy in early 
phase clinical trials when they were utilized in adoptive 
immunotherapy. Recent studies have demonstrated that 
cells with the Vδ1 chain and those with neither Vδ1 nor Vδ2 
chains have properties which may make them more 
attractive anticancer effectors in adoptive immunotherapy 
[1]. 
By contrast, other reports have revealed an unexpected 
series of protumor functions of γδ T cells in mouse models 
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and human patients. In particular, specific γδ T-cell subsets 
are capable of recruiting immunosuppressive myeloid 
populations, inhibiting antitumor responses, and enhancing 
angiogenesis, thus promoting cancer progression. A 
common mediator of such functions appears to be the 
cytokine IL17, whose pathogenic effects can override the 
antitumor immune response orchestrated by IFNγ [2]. 
The implications for the manipulation of γδ T cells in cancer 
immunotherapy is an important field of study.  
The first part of this work introduces general immunology 
aspects and afterwards describes T lymphocytes γδ T cells 
subpopulation, specifically their features and biological 
functions, their identification and activation methodologies. 
More concretely, we have studied that population over 
prostatic tissue samples, taken from multiple biopsies 
coming from subjects who potentially have a prostate tumor 
on the basis of high serum PSA combined with digital rectal 
exploration of the prostate. 
Based on this, the aim of this research has been to evaluate 
the frequency, the phenotype and the effector function of 
prostate cancer-infiltrating δ1 and δ2 T cells in prostatic 
biopsy samples and the correlation of these data with the 
11 
presence of cancer versus healthy tissues and, in cancer 
tissues, with Gleason pattern. The analysis has been 
performed in circulating γδ T cells of the same patients and 
as control in healthy subject who, after transrectal echo 
guided prostatic biopsy, did not receive cancer diagnosis. 
Given that γδ T cells mediate antigen-specific killing of 
tumor cells, we also studied the representation and the in 
vitro cytokine production, in particular interferon γ and 
interleukin 17. 
12 
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Chapter 1 
Prostate Cancer 
1.1 Introduction 
Prostate cancer has been the most common noncutaneous 
malignancy in U.S. men since 1984, now accounting for one 
quarter of all such cancers (American Cancer Society, 2008). 
The estimated lifetime risk of disease is 16.72%, with a 
lifetime risk of death at 2.57%. Prostate cancer incidence 
varies by race/ethnicity, with African-Americans at highest 
risk. The incidence of prostate cancer peaked in 1992 
(approximately 5 years after introduction of the prostate-
specific antigen [PSA] screening test). 
Incidence rates show that prostate cancer is the fifth most 
common malignancy worldwide and the second most 
common in men [3]. Prostate cancer makes up 11.7% of new 
cancer cases overall, 19% in developed countries, and 5.3% 
in developing countries. Its incidence varies widely between 
countries and ethnic populations, with disease rates 
differing by more than 100-fold. The lowest yearly incidence 
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rates occur in Asia (1.9 cases per 100,000 in China) and the 
highest in North America and Scandinavia, especially in 
African-Americans (249 cases per 100,000). 
Prostate cancer is rarely diagnosed in men younger than 50 
years old, accounting for only 2% of all cases [4]. The median 
age at diagnosis is 68 years.  
In addition to changes in prostate cancer incidence and 
mortality over the last several decades, there has been a 
substantial shift to more favorable stage at presentation in 
men with newly diagnosed disease. This clinical stage 
migration is largely if not exclusively accounted for by PSA 
screening Since the introduction of PSA testing, the 
incidence of local-regional disease has increased, whereas 
the incidence of metastatic disease has decreased Non 
palpable cancers (American Joint Committee on Cancer 
[AJCC] clinical stage T1c) now account for 60% to 75% of 
newly diagnosed disease Clinical stage migration has also 
been associated with improvements in 5- and 10-year 
disease-specific survival [5-7]. 
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These observations have been consistent across the United 
States and Europe [8,9] 
 
1.2 Risk Factors 
Although the specific causes of prostate cancer initiation 
and progression are not yet known, considerable evidence 
suggests that both genetics and environment play a role 
in the origin and evolution of this disease. Traditional and 
molecular epidemiology have identified a number of 
potential risk factors associated with the development of 
prostate cancer. 
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1.3 Familial and genetic 
Ample epidemiologic evidence suggests that prostate 
cancer has both a familial and genetic component. 
Results of a meta-analysis demonstrate that relative risk 
increases according to the number of affected family 
members, their degree of relatedness, and the age at which 
they were affected [10]. 
Sporadic cancers account for about 85% of all prostate 
cancers and about 15% are familial and/or hereditary. 
Hereditary prostate cancer accounts for 43% of early onset 
disease (55 years of age or younger) but only 9% of all 
cancers that occur by 85 years of age [11]. 
 
1.4 Inflammation 
Chronic inflammation leading to cellular hyperproliferation 
to replace damaged tissue contributes to the development 
of infection-associated cancers of the colon, esophagus, 
stomach, bladder, and liver [12]. Accumulating 
epidemiologic, histologic, and genetic evidence suggests 
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that a similar process may underlie the development of 
prostate cancer. 
Inflammatory infiltrates and the histologic lesion called 
proliferative inflammatory atrophy (PIA) are frequent in 
clinical prostate specimens [13]. PIA is a spectrum of lesions 
characterized by epithelial atrophy, low apoptotic index, and 
an increased proliferative index usually associated with 
inflammatory infiltrates. Inflammation in PIA may include 
mononuclear infiltrates in the stroma and macrophages 
and/or neutrophils in the glandular lumen or epithelium. 
Macrophages activated by interferon-γ secrete 
proinflammatory cytokines and reactive nitrogen species 
(e.g., nitric oxide). Inducible nitric oxide synthase, which 
catalyzes the generation of nitric oxide, is overexpressed in 
macrophages in PIA but not in normal epithelium. PIA 
appears to be a regenerative lesion appearing as a 
consequence of infection or cell trauma resulting from 
oxidant damage, hypoxia, infection, or autoimmunity, and 
its hyperproliferative state may lead to cancer. PIA is often 
found adjacent to high-grade prostatic intraepithelial 
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neoplasia (HGPIN) or early cancer and there is an identifiable 
genetic pathway between PIA, HGPIN, and cancer [14-16], 
see figure 1. 
 
Figure 1 Genetic pathway  
 
The previously described genetic and histologic 
observations in prostate cancer strongly suggest that 
compromised cellular defenses against inflammatory 
oxidants may initiate and/or perpetuate prostatic 
carcinogenesis. 
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1.5 Other factors 
Androgens influence the development, maturation, and 
maintenance of the prostate, affecting both proliferation 
and differentiation of the luminal epithelium. There is little 
doubt that exposure of the prostate at key developmental 
times to androgens plays an important role in prostate 
carcinogenesis. Androgens are also important in the 
maintenance of established cancers, as supported by the 
historical observation that the majority of prostate cancers 
initially respond to androgen-deprivation therapy, and more 
recently by results of the Prostate Cancer Prevention Trial, 
which indicated that inhibition of the conversion of 
testosterone to the more potent dihydrotestosterone by 
finasteride reduces the incidence of prostate cancer by 
approximately 25% [17]. In addition, genetic polymorphisms 
of the androgen receptor (AR) [18, 19] the 5α-reductase type 
2 isoenzyme [20], and the genes involved in biosynthesis of 
testosterone have also been implicated in prostate 
carcinogenesis [21].  
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Vitamin D (1, 25 dihydroxyvitamin D3) is an essential vitamin 
that is a part of the steroid hormone superfamily. Human 
sources include both dietary intake and conversion from an 
inactive to active vitamin D in the skin through sunlight 
exposure. Interest in vitamin D as a determinant of prostate 
cancer risk comes from several epidemiologic observations 
[22]:  
1. Men living in northern latitudes with less exposure to 
sunlight-derived ultraviolet exposure have a higher 
mortality rate from prostate cancer. 
2. Prostate cancer occurs more frequently in older men, in 
whom vitamin D deficiency is more common both because 
of less ultraviolet exposure and age-related declines in the 
hydroxylases responsible for synthesis of active vitamin D. 
3. African-Americans, whose skin melanin blocks ultraviolet 
radiation and inhibits activation of vitamin D, have the 
highest worldwide incidence and mortality rates for prostate 
cancer. 
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4. Dietary intake of dairy products rich in calcium, which 
depresses serum levels of vitamin D, is associated with a 
higher risk of prostate cancer. 
5. Native Japanese, whose diet is rich in vitamin D derived from 
fish, have a low incidence of prostate cancer. 
 
In addition, prostate cancer cells express the vitamin D 
receptor, and several studies have demonstrated an 
antiproliferative effect of vitamin D on prostate cancer cell 
lines by inducing cell cycle arrest [23]. 
Many studies show no or a weak association between 
vitamin D levels and prostate cancer risk [24-27]. The 
Cancer Prevention Study II Nutrition Cohort, a prospective 
cohort of 65,321 men demonstrated a modestly increased 
relative risk of 1.2 for total calcium intake (dietary and with 
supplements) and 1.6 for high dietary calcium intake alone 
(≥2000 vs. <700 mg/day), but not for dairy intake [28]. The 
results suggest that very high calcium intake, above daily 
recommendation, may modestly increase risk. These 
conflicting results regarding vitamin D, calcium, and 
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prostate cancer risk may be explained by variants in the 
vitamin D receptor (VDR). Polymorphisms resulting in a VDR 
with lower activity have been associated with increased risk 
for prostate cancer, as well as with increased risk of 
biochemical recurrence following radical prostatectomy [29-
31]. 
 
1.6 Prostate cancer pathology 
Most prostate cancers are adenocarcinomas (95%).  
Although numerous grading systems exist for the evaluation 
of prostatic adenocarcinoma, the Gleason grading system is 
the most widely accepted [32]. The Gleason system is based 
on the glandular pattern of the tumor as identified at 
relatively low magnification Cytologic features play no role 
in the grade of the tumor. Both the primary (predominant) 
and the secondary (second most prevalent) architectural 
patterns are identified and assigned a grade from 1 to 5, 
with 1 being the most differentiated and 5 being the 
least differentiated. Because both the primary and the 
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secondary patterns are influential in predicting 
prognosis, there is a Gleason sum or score obtained by 
the addition of the primary and secondary grades. If a 
tumor has only one histologic pattern then for uniformity, 
the primary and secondary patterns are given the same 
grade.  
Prostatic intraepithelial neoplasia (PIN) is characterized by 
cytologically abnormal cells lining existing prostatic ducts 
and acini, and is classified as either low- or high-grade 
(LGPIN, HGPIN). HGPIN most commonly occurs in the 
peripheral zone of the prostate (75 to 80% of cases) and 
rarely in the central zone (5% of cases). HGPIN is very 
common in specimens from radical prostatectomy (85 to 
100% of cases). This finding, along with other evidence, 
suggests a strong link between HGPIN and carcinoma of the 
prostate. 
PIN can be recognized microscopically at low magnifications 
by three main characteristics: darker lining of ductal 
structures, thicker lining compared to ducts and acini in 
surrounding normal tissue, and complex intraluminal 
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growth. Three characteristics at high magnification are: 
nuclear enlargement and stratification, hyperchromasia, and 
prominence of nucleoli.  
It appears that high-grade PIN is a precursor lesion to many 
peripheral intermediate- to high-grade adenocarcinomas of 
the prostate. However, PIN need not be present for 
carcinoma to arise.  
 
1.7 Prostate biopsy 
Early prostate cancer detection has benefited greatly from 
prostate-specific antigen (PSA) screening efforts, the 
introduction and refinement of systematic transrectal 
ultrasonography (TRUS)–guided prostate biopsy techniques, 
and increased public awareness about prostate cancer. 
Prostate cancer's potential long natural clinical history is 
reflected in tumors found during autopsies carried out 
following other causes of death. The incidence of latent or 
autopsy cancer is much greater than cases of clinical cancer. 
The biopsy grade, clinical stage, PSA level and, when 
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available, the results of imaging studies can provide such 
prognostic information. Several treatments are available: 
radical prostatectomy and conformational radiotherapy for 
localized disease are potentially curative therapies; 
hormonal therapies (antiandrogenic) is the treatment of 
choice for advanced and metastatic disease. In 
asymptomatic, well selected and informed men, an active 
surveillance may be an option [7, 33]. Patients with 
androgen-indipendent prostate cancer have a median 
survival of only 20 months despite of the new 
chemotherapeutic therapies, docetaxel based. 
The lack of effective and curative therapies for Hormon 
Refractory Prostate Cancer (HRPC) has fueled an intensive 
search for novel modalities, including immunotherapy 
[34,35]. 
The first step for the characterization of prostate cancer is 
the exact diagnosis and stadiation of the disease. The 
suspicious of prostate cancer derives from an elevated 
prostatic specific antigen (PSA) value and/or a suspected 
determination of the prostate during the digital rectal 
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examination. In case of suspected prostate cancer, the 
definitive exact diagnosis is made only by the prostate 
biopsy that is today performed under ultrasonographic 
transrectal guide. 
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Chapter 2 
2.2 γδ T Cell 
γδ T lymphocytes are important effector cells that may play a 
critical role in cancer immune surveillance [37] and  recent 
clinical trials support their use as immunotherapeutic 
agents, either via the adoptive transfer of ex vivo expanded 
γδ T cells or following the activation of γδ T cells in vivo, by 
compounds such as phosphoantigens or 
aminobisphosphonates [38-39]. 
γδ T cells can be divided into three main populations based 
on δ chain expression, phenotypic and functional 
parameters: γδ T cells expressing the Vδ1 T-cell receptor 
(TCR) chain, which are mostly found in mucosal tissues, 
where they are involved in maintaining epithelial tissue 
integrity when facing damage, infection, or transformation, 
responding to stress antigens on epithelial cells and 
producing IL-10 but little or no IL-2, IL-4 or IFN γ. The second 
population of  γδ T express  Vδ2 TCR chain, products and 
represents the majority of circulating γδ T lymphocytes in 
healthy human adults, comprising up to 50%–90% of the 
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peripheral γδ T-cell population  and secondary lymphoid 
organs [40 ]. The Vδ2 chain pairs almost exclusively with Vγ9 
(also termed Vγ2). One attractive feature of Vδ2 T cells is that 
they can serve as professional antigen-presenting cells (APC) 
[41]. 
Activated Vδ2 T cells acquire characteristics of professional 
APC, such as the expression of antigen presenting, co 
stimulatory, and adhesion molecules, including MHC-II, CD80, 
and CD86. It is worthy of note that rapamycin or IL-18 
treatment is reported to increase the expression of MHC-II, 
CD80, and CD86 on Vδ2 T cell lines [42]. The third population 
is Vδ3 T cells, which take up about 0.2% of circulating T cells 
including CD4+, CD8+, and CD4-CD8- subsets. They are 
expressed CD56, CD161, HLA-DR, and NKG2D but without 
NKG2A and NKG2C. The Vδ3 T cells are found only a little in 
blood but are rich in liver and in patients with leukemias and 
some chronic viral infections. Through mitogen stimulation 
with IL-2, Vδ3 T cells were expanded to recognize CD1d. 
Once activation, they can kill CD1d+ target cells, release 
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cytokines such as Th1, Th2, and Th17, and induce maturation 
of dendritic cells (DCs) into APCs [43]. 
It is currently believed that, due to their extremely limited 
diversity, Vδ1 T cells may not respond to a diversity of 
microbial antigens but rather to unique “stress antigens” 
that are markers of cell infection or transformation. Vδ1 T 
cells reside mainly within epithelial tissues such as the 
intestinal epithelium and epidermis, where they might 
provide a first line of immunosurveillance against 
malignancy by recognizing ligands such as MHC Class I-
related molecules (i.e., MICA and MICB), whose expression 
can be induced in response to infection, injury or cellular 
transformation [44]. These molecules have no role in the 
presentation of peptide antigens, but may function 
themselves as tumor associated antigens. Vδ1 T cells can 
inhibit tumor cell growth and recruit other immune cells by 
releasing a number of cytokines, including tumor necrosis 
factor α and interferon γ. Because of Vδ1 T cells reside mainly 
within epithelial tissues, we consider prostate cancer an 
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appropriate model to study the antitumor properties of Vδ1 
T cells [36].  
T cells expressing the Vδ2 gene usually account for more 
than 90% of the circulating γδ T-cell pool (representing 
about 1–10% of human peripheral lymphocytes), while 
intraepithelial γδ T cells more commonly express the Vδ1 
gene. Although no major differences exist relative to effector 
functions between T cells expressing the aß TCR and γδ T 
cells, the latter are capable of recognizing tumor-associated 
ligands that are neglected by conventional aß T cells in an 
MHC-independent manner [48]. Many preclinical studies and 
clinical trials have focused their attention on Vγ9Vδ2 T cells, 
as they can be easily isolated from the peripheral blood of 
most individuals and activated with conventional drugs such 
as synthetic phosphoantigens and aminobisphosphonates, 
see Fig.2. 
The Vγ9Vδ2 displays a broad reactivity against microbial 
agents and tumors, recognize both microbial metabolites 
(intermediates of the non-mevalonate pathway of 
isoprenoid biosynthesis) and endogenous metabolites of the 
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mevalonate pathway, whose production is up-regulated 
upon cell stress.  
 
 
Figura 2 Nonpeptide antigens for γδ T cell stimulation. 
 
2.2 γδ T cell receptor  
Functional responses by γδ T cells can be stratified by the 
variable (V) region of the TCRδ chain. In humans, the TCRδ 
locus (TRD) lies within the TCRα locus (TRA). Three unique Vδ 
alleles, TRDV1, TRDV2, and TRDV3, code for TCRδ1, TCRδ2, 
and TCRδ3, respectively. Additionally, shared Vδ and Vα 
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variable regions exist in TRDV4/TRAV14, TRDV5/TRAV29, 
TRDV6/TRAV23, TRDV7/TRAV36, and TRDV8/TRAV38-2 loci.  
Recombination of these shared V alleles with a TRA junction 
region (TRAJ ) results in TCRα14, TCRα29, TCRα23, TCRα36, 
and TCRα38-2, respectively, but recombination of the shared 
V alleles with TRD junction(TRDJ) and diversity(TRDD) 
regions resultsinTCRδ4, TCRδ5, TCRδ6, TCRδ7, andTCRδ8, 
respectively (13). Expression of TCR γδ heterodimers on the 
T-cell surface in the thymus inhibits recombination of TCRb-
chain locus during the CD4neg CD8neg stage there by 
committing the T cell to the γδ T-cell lineage [45]. This 
double negative status is typically maintained up on exit 
from the thymus, most likely because co-receptors are 
dispensable for functional TCR γδ binding to antigens [46]. 
However, the thymus is not required to complete all γδ T-cell 
development, as many γδ T cells directly take up residence 
in peripheral tissues following exit from the bone marrow 
and exhibit immediate effector functions against pathogens 
[47]. Human TCR γδ ligands are MHC/peptide complex-
independent and are therefore conserved among stun 
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related individuals. Most of the known human ligands are 
specific for TCRδ1 orTCRδ2. TCRg1/TCRδ1 
(alternativelytermedVγ1Vδ1) heterodimers have specificity 
for MHC Class-I chain-related A (MICA) [48], a molecule 
participating in evasion of immune surveillance following  
viral infection and expressed on tumor cells as it is involved 
in the cellular stress response [49]. In contrasttoVδ1 andVδ2 
cells, very little is known about human γδ T cells expressing 
other TCR γδ alleles except for indirect evidence ofVδ3 cell’s 
immunity against CMV and HIV [50]. Given the multivalent 
nature of γδ T cells, harnessing γδ T cells populations with 
polyclonal TCR repertoire is attractive for adoptive 
immunotherapy. 
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Classification and Funtions of γδ T cells 
2.3 Classification and Funtions of γδ T cells 
γδ T cells are distinguished from their αβ T cell counterparts 
by utilizing a distinct set of somatically rearranged variable 
(V), diversity (D), joining (J), and constant (C) genes. 
Compared to αβ T cells, available germ line repertoires of Vγ 
and Vδ genes are limited. γδ T cells contain fewer V, D, and J 
segments than αβ T cells. Regarding evolutionary forces that 
shape the V, D, and J gene segments, distinct forces were 
involved in the formation of the γ and δ loci. In fact, the 
primate Vγ and Jδ genes are highly conserved, whereas, the 
γ-locus is split: the Vγ9, Vγ10, and Vγ11 genes represent the 
conserved region of the Vγ gene locus, but the remaining Vγ 
genes have been evolving rapidly [51]. 
Similar to CD4 and CD8 T cells, Vγ9Vδ2 T lymphocytes are 
heterogeneous and comprise distinct populations that can 
be distinguished on the basis of surface marker expression 
and effector functions, such as cytokine secretion and 
cytotoxicity, [52]: naive (Tnaive) CD45RA+CD27+ and central 
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memory (TCM) CD45RA–CD27+ cells that express lymph 
node homing receptors, abound in lymph nodes and lack 
immediate effector functions, effector memory (TEM) 
CD45RA–CD27– and terminally differentiated (TEMRA) 
CD45RA+CD27– cells that express receptors for migration to 
inflamed tissues, are poorly represented in the lymph nodes 
while abounding at sites of inflammation, where they 
display immediate effector functions [53], as shown in Fig 3 .  
 
Figura 3 Phenotype of γδ T cells 
 
The Vδ2 T cells are endowed with a variety of effector 
functions that contribute to antitumor immune responses. 
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They can produce different kinds of cytokines and 
chemokines such as interferon-γ (IFN-γ) and tumor necrosis 
factor- α (TNF-α), and growth factors such as IGF-1. Besides, 
they can regulate immune responses via interactions with 
other cells, for example, they can provide help for B cells and 
present antigens for αβ T cells. 
Human γδ T cells induced DC maturation [54] via TCR-CD1 
[55] and Fas–FasL interactions [56]. Because DCs are 
uniquely resistant to Fas-induced cell death, Fas-FasL 
interaction can transduce maturation signaling. When 
human Vγ9Vδ2 T cells were co-cultured with iDCs, they 
induced increased expression of CD86 and MHC class I on 
iDCs [57], mainly via γδ T cell-derived TNF-α and IFN-γ. DC 
maturation induced by LPS was further enhanced by γδ T 
cells [58]. Fourthly, γδ T cells are involved in the macrophage 
recruitment. 
γδ T cells produce growth factors that maintain epidermal 
integrity. γδ T cells in psoriasis, an immune mediated disease 
associated with hyperproliferation of keratinocytes and 
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angiogenesis, have been showed to produce growth factors 
like IGF-1, VEGF and FGF-2 [59]. 
The Vδ2 T cells are endowed with a variety of effector 
functions that contribute to antitumor immune responses. In 
particular, γδ T cells can mediated cytotoxic activity against 
cancer cells, produce Th1- associated cytokines and cross-
talk with dendritic cells, macrophages and B cells. Under 
appropriate conditions, γδ T cells may divert from their 
typical Th1-like phenotype and polarize toward Th2, Th17, 
and regulatory T cells (Tregs), all of which (at least 
potentially) inhibit antitumor immune responses [53,60].  
Activated γδ T cells exhibit broad cytotoxic activity against a 
wide variety of tumor cells, in which they utilize death 
receptor/ligand (e.g. Fas/Fas-ligand)-dependent and 
perforin/granzyme or granulysin-dependent pathways. γδ T 
cells secrete various cytokines [61] and chemokines 
including proinflammatory Th1-like cytokines such as IFN-γ 
and TNF-α, and contribute to reduced survival of autologous 
tumor cells [62], Fig.4-5. Besides, they also produce Th2 
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cytokines such as IL-4 in the broncho alveolar lavage fluid of 
patients with allergic asthma [63-64],  
 
Figura 4 Receptors  of γδ T cells 
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Figura 5 Schematic Funtions of γδ T cells 
 
γδ T cells have been reported to secrete interleukin-10 (IL-
10) [65], controlling CD8+ T cell expansion and regulating 
TNF-α secretion by activated CD8+ T cells, and IL-17 [66], 
regulating the expansion and recruitment of neutrophils and 
monocytes to initiate inflammatory responses. The role of IL-
17-producing γδ T cells has been evaluated in various 
models of infection [67] and autoimmunity. Secretion of 
multiple cytokines and chemokines by activated γδ cells and 
their physiological roles are shown in Fig. 6 
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Recent studies have revealed that a high frequency of γδ T 
cells infiltrating renal cell carcinoma lesions failed to 
correlate with prognostic features, and in a group of breast 
cancer patients the amount of intratumoral γδ T cells 
correlated positively with advanced tumor stages and lymph 
node metastasis [68], but inversely with both relapse-free 
and overall survival. 
Such functions are attractive weapons for immunotherapy 
strategies, and there are promising results from recent, 
relatively small-scale applications of Vγ9Vδ2 T cells to 
hematologic [69] and solid-tissue malignancies, including 
prostate cancer [70] and advanced renal cell carcinoma [71].  
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Figura 6 Secretion by activated γδ cells of multiple cytokines and their physiological 
roles. 
 
2.4 Immune surveillance 
In the 1950s, Frank MacFarlane Burnet an Lewis Thomas 
formulated the 'immune surveillance' hypothesis, in which 
cells of the immune systems would detect and destroy 
tumor cells. Since then, it has become clear than that 
relationship between the immune system and cancer is 
considerably more complex, and this hypothesis has been 
modified to consider three phase of tumor growth. The first 
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is the 'elimination phase,' in which the immune system 
recognizes and destroys potential tumor cells- the 
phenomenon previously called immune surveillance. If 
elimination phase is not completely successful, what follows 
is an 'equilibrium phase,' in which tumor cells undergo 
changes or mutations that aid their survival as a result of the 
selection pressure imposed by the immune system. During 
the equilibrium phase, a process known as “cancer 
immunoediting” continuously shapes the properties of the 
tumor cells that survive. In the final 'escape phase,' tumor 
cells that have accumulated sufficient mutations elude the 
attentions of the immune system and grow unimpeded to 
become clinically detectable. According to the 
immunoediting hypothesis, those tumor cells that survive 
the equilibrium phase have acquired additional mutations 
that prevent their elimination by the immune system. In an 
immunocompetent individual, the equilibrium immune 
response continually removed tumor cells, delaying tumor 
growth; if the immune system is compromised, the 
equilibrium phase quirkily turns into escape, as no tumor 
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cells at all are removed. Another situation in which the 
breakdown of immune surveillance can lead is tumor 
development in post-transplant lymphoproliferative 
disorder, which can occur when patients are 
immunosuppressed after, for example, solid organ 
transplantation. It usually takes form of a B-cell expansion 
driven by Epstein-Barr virus (EBV) in which the B cells can 
undergo mutations and become malignant. Immune 
surveillance therefore seems to be critical for the control of 
virus-associated tumors [72]. 
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Chapter 3 
3.1 Immunotherapy 
Immunotherapy is the treatment of cancer or 
inflammatory/autoimmune disease by inducing, enhancing 
or suppressing an immune responce. Immunotherapy can 
be nonspecific or (antigen) specific. Nonspecific 
Immunotherapy aims to enhance the overall host immune 
response, whereas specific immunotherapy targets the 
immune system against a particular tumor or increases 
tolerance towards a specific allergen. There are four 
immunotherapy: adoptive immunotherapy, antibody-based 
immunotherapy, cancer vaccine therapy and allergen-
specific immunotherapy. From these, adoptive and antibody 
based immunotherapies are passive approaches, whereas 
cancer vaccine therapy and allergen-specific 
immunotherapy are active approaches. Despite advances in 
oncological research, cancer remain a leading cause of death 
throughout the developed world. Nonspecific approaches to 
cancer treatment, such as surgery, radiotherapy and 
46 
 
generalized chemotherapy, have been successful in the 
management of a distinct group of leukemias and slow 
growing solid cancer. Immunotherapy is an emerging 
alternative area of cancer treatment. Cancer immunotherapy 
includes both passive and active strategies. Passive 
immunotherapy involves the ex vivo creation of established 
tumor-immune elements (antibodies, immune cells) that are 
administered to patients to mediate anti-tumor activity 
directly or indirectly, and which do not stimulate the host 
immune system. In contrast active immunotherapy induces 
a tumor-specific immune response in the patients, leading to 
the production of specific immune effectors (antibodies and 
T-cells).  
 
3.2 Nonspecific Immunotherapy 
1) Bacillus Calmette-Guerin (BCG) is the most effective 
intravesical nonspecific immunotherapeutic agent, and is 
used for the prevention and treatment of superficial bladder 
cancer. The proposed anti-tumor mechanism of BCG involves 
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activation of the immune system and the promotion of a 
local acute nonspecific inflammation in the bladder lumen. 
Immune cells activation in response to BCG is mediated by a 
family of transmembrane recognition receptors called Toll 
Like receptors 
2) Cytokine are low-molecular-weight, soluble proteins that 
regulate the innate and adoptive immune system. The anti-
tumor activity of cytokines is mediated by one of two 
general mechanism: first, a direct anti-tumor effect, and 
second, indirect enhancement of the anti-tumor immune 
response. It has been hypothesized that both the cytokine-
activated lymphocytes and their secretory products such as 
interferon gamma and tumor necrosis factor-beta may 
contribute to the lisys  of tumor cells in vivo. [73-74] 
 
3.3 Specific immunotherapy  
1) Adoptive Immunotherapy involves the infusion 
immunologically- component, ex vivo-expanded, donor-
derived lymphocytes, which specifically destroy tumor cells 
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by graft-versus leukemia or graft-versus tumor effect. In 
addition, peripheral blood-derived lymphokine activated 
killer cells and tumor-infiltrating lymphocytes derived from 
tumor section have proven to be effective anti-tumor agents  
To address MHC and exogenous cytokine-indipendent 
activation of anti-tumor effector function, T cells can be 
engineered of a recognition unit and an intracytoplasmic 
signaling molecule. Such receptors can be used to target 
various type of effectot cells including cytotoxic T-cells 
towards any tumor-associated antigen for which there is a 
suitable antibody. 
2) Antibody based immunotherapy exploits the higly specific 
binding between antibodies and their corresponding tumor-
associated antigens, resulting in some significant clinical 
response. Tumor-associated antigens are structures 
presented predominantly by tumor cells, thereby allowing 
antibodies to distinguish tumors from non-malignant tissue. 
Therapeutic monoclonal antibodies can destroy tumor cells 
directly by inducing apoptosis or indirectly through 
immunological mechanism such as antibody-dependent 
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cell-mediated cytotoxicity and or complement- dependent 
cytotoxicity. In addition, the natural function of antibodies 
can be enhanced by conjugating them to toxins, 
radionucleotides, liposomes and cytotoxix drugs. Host 
immune responces can be enhanced through the induction 
of anti-idiotypic antibodies or through the use of bispecific 
antibodies containing arms with different specificities. 
3) Cancer vaccine therapy represents an active, systemic, 
tumor-specific immune response of host origin. It is used 
either to treat existing cancers or to prevent cancer 
development. There are several types of cancer vaccine: 
isolated whole cell cancer vaccines or tumor cell lysates, 
protein- or peptide-containing vaccines, viral vector vaccines 
and anti-idiotype vaccines. Following the administration of a 
vaccine-antigen that resembles a specific target, the 
patient’s humoral and T-cells-specific immune response 
induces defence mechanism to combat the target in vivo 
4) Cytokine Receptor as the Target for immunotherapy and 
Immunotoxin Therapy 
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Cancer immunotherapy attempts to stimulate the immune 
system to reject and destroy tumors. For example, 
administration to interferon can activate the systemic 
immunity. Cancer vaccines take advantage of the fact that 
certain molecules on the surface of cancer are either unique 
or more abundant than those found on normal or 
noncancerous cells. These molecules act as antigens, 
stimulating the immune system to evoke a specific immune 
response. Immunotoxin are protein toxin connected to a cell 
binding ligand or antibody. Classically, immunotoxins were 
created by chemically conjugating an antibody to a whole 
protein toxin, or, for more selective activity, by using a 
protein toxin devoid of its natural binding domain. Targeted 
cancer therapy such us immunotoxin therapy which target 
tumor-specific cells surface receptors is one of the most 
effective strategies against cancer. The targeted agents 
require a threshold level of receptor expression on the 
cancer cells to achieve their antitumor activity [73-74]. 
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Chapter 4 
4.1 How can tumor-infiltrating lymphocytes kill 
tumours? 
 
The treatment of patients with cell populations that have 
been expanded ex vivo is called adoptive cell transfer (ACT). 
Cells that are infused back into a patient after ex vivo 
expansion can traffic to the tumour and mediate its 
destruction. ‘Preparative lymphodepletion’ the temporary 
ablation of the immune system in a patient with cancer can 
be accomplished using chemotherapy alone or in 
combination with total-body irradiation, and the addition of 
this step is associated with enhanced persistence of the 
transferred T cells.  
 During the process of expanding TIL populations in 
culture, tumour cells die or are killed by activated natural 
killer (NK) cells or newly expanding T cell populations. The 
TILs are dissociated from immunosuppressive cell 
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populations such as myeloid-derived suppressor cells 
(MDSCs) and possibly exposed to lower levels of 
immunosuppressive cytokines during this early period in 
culture. The ex vivo expansion of TIL populations to more 
favourable numbers followed by the transfer of these cells 
back into the host can trigger the death and complete 
eradication of the tumour, leading to the durable and 
complete remission and even the ‘cure’ of established 
cancers [52]. MHC class I-restricted T cells that are specific for 
tumours (either naturally or as a result of gene engineering) 
are, theoretically, capable of directly recognizing many types 
of tumour cells, because virtually every nucleated cell in the 
body expresses MHC class I molecules. However, neoplastic 
cells are notoriously unstable targets, as these cells often 
downregulate their expression of MHC class I molecules 
[68,75, 76]. Professional APCs process exogenous antigens 
and present them to T cells in the context of MHC class II 
molecules, or in the context of MHC class I molecules 
through a mechanism known as cross-priming. Such indirect 
recognition of tumour-associated antigens by T cells might 
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provide an effective means of targeting tumour masses that 
have lost MHC expression by triggering innate immunity and 
vascular collapse.  
Immune surveillance might eliminate many microscopic 
tumours before they become evident and, based on 
experiments in mice, some investigators have proposed that 
tumors experience immunoediting. However, tumor masses 
that grow uncontrollably and ultimately kill their hosts 
demonstrably express immunologically targetable antigens. 
Thus, not only do tumor masses ‘escape’ recognition by 
eliminating antigenic targets that they express, but they also 
coopt or render insufficient the adaptive immune system of 
the host [77,78]. After transformation, tumor cells generally 
continue to express antigens that are characteristic of their 
tissue site of origin. Tissue-differentiation antigens can be 
excellent targets for ACT-based therapy, but only for tissues 
that are not essential for life. By sharp contrast, populations 
of TILs can be given usually without causing evidence of eye 
or ear toxicity, despite having TCRs specific for the same 
non-mutated self antigens. The induction of long-term, 
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durable immune responses, which can kill all of the tumor 
cells, can usually be accomplished by the transfer of TILs 
without causing the toxicity attributable to T cells. This 
suggests that the naturally occurring TILs in prostate cancer 
might respond to antigens other than non-mutated self 
antigens. Immunotherapy based on the adoptive transfer of 
tumor-specific lymphocytes has a rich history that dates 
back several decades [79]. It is important to distinguish these 
ACT-based treatments from other immunotherapies, such as 
therapeutic cancer vaccines, which are aimed at boosting 
immune reactivity in the tumor-bearing host. Therapeutic 
vaccines are attractive because they are easy to use and 
have shown low toxicities in preclinical and clinical trials at 
the US National Cancer Institute and elsewhere [80,81]. 
Vaccines can be augmented using prime–boost regimens, 
MHC anchor modifications, cytokines and co-stimulation 
[82,83]. However, broad reviews of clinical trials show that 
cancer vaccines only induce objective tumour regression in 
less than 4% of patients treated [84,85]. Immunotherapies 
based on the adoptive transfer of TILs are the best available 
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treatment for patients with metastatic melanoma. However, 
these therapies have limitations. Not all patients can be 
entered into trials, as they are still limited to patients with 
good performance status who are capable of withstanding 
the rigours of the lymphodepletion and IL-2 based 
treatments that are currently used. Chimeric antigen 
receptors (CARs) are another means for providing specificity 
to transduced T cells and can originate from antibodies. The 
variable regions from antibody genes can be engineered to 
encode single-chain structures fused to TCR intracellular 
domains that are capable of activating T cells. Recombinant 
retroviruses can then be used to transduce T cells with the 
CAR, which has antibody-like specificity. Thus, CARs 
recognize MHC-nonrestricted structures on the surfaces. of 
target cells, whereas TCRs recognize mainly intracellular 
antigens that have been processed and presented as 
peptide complexes with MHC molecules. Finally, it is worth 
noting that, rather than engineering the T cells themselves, 
another approach that can be used to promote T cell 
recognition of tumors is to engineer bispecific antibodies 
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[86,87]. One subgroup of these, known as bispecific T cell 
engagers (BITEs), can promote tumour elimination by linking 
T cells to tumors, even in the absence of cognate TCR–MHC 
interactions. 
In the previous paragraphs, we have elaborated on the 
mechanism of ligand recognition, activation, cytokine 
secretion, and applications of γδ T cells. To be understood 
better, we summarized the above-mentioned contents in Fig 
7 and 8. 
 
4.2 γδ T Cells and Their Potential for 
Immunotherapy 
There is good evidence that tumor can naturally be 
controlled by the immune system, and most 
immunotherapy strategies aim to induce adoptive, tumor-
specific responses of B cells and MHC- restricted αβ T cells, 
particularly CD8 T cells [37, 75, 76, 88]. The regressing tumor 
lesions are often markedly infiltrated by mononuclear cells 
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and the presence of T lymphocytes has been associated with 
improved prognosis in patients affected by different types of 
cancer [37] γδ T cells are a natural component of resistance 
to cutaneus carcinogenesis in mice [76] and in humans 
display potent MHC-unrestricted cytotoxic activity in vitro 
against varius tumors, including prostate cancer cell line 
[96]. Human Vγ9Vδ2 T cells expanded ex vivo and then 
adoptively transferred to severe combined immunodeficient 
mice xenografted with tumor cells showed efficacy against 
B-cell lymphoma, renal and pancreatic carcinoma [89]. 
Bulding on this, the potential of human γδ T cells for tumor 
immunotherapy has been analyzed and was recently 
expertly reviewed [90]. 
γδ T cells possess a combination of innate and adaptive 
immune cell qualities rendering them attractive for 
immunotherapy [106–108]. They can produce inflammatory 
cytokines, directly lyse infected or malignant cells, and 
establish a memory response to attack pathogens upon re-
exposure.  
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The most potent antitumor cytolytic mediators are γδ T cells, 
innate-like lymphocytes that recognize their targets 
independently of major histocompatibility complex (MHC)–
mediated antigen presentation [71,91]. Human γδ T cells kill 
a vast repertoire of tumor cell lines and primary samples in 
vitro, including leukemia and lymphoma, melanoma, 
neuroblastoma, and multiple types of carcinoma [92-96]. 
More recently, in vitro–activated γδ T cells have also been 
shown to target a small population of colon cancer stem 
cells, responsible for tumor resistance to conventional 
therapies [96], and to kill chemotherapy and imatinib–
resistant chronic myelogenous leukemia lines [93]. 
Moreover, γδ T cells have been frequently isolated from 
tumor-infiltrating lymphocytes and shown to react in vitro to 
tumors but not to healthy cells [71]. The activated human γδ 
T cells produce large amounts of interferon- γ [97], a central 
cytokine in antitumor immune responses. 
Hematopoiesis is regulated by several cytokines with 
pleiotropic activity. Several evidences have clearly 
demonstrated that these molecules, formerly regarded as 
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specific for the hematopoietic system, also affect certain 
endothelial cell functions and that hematopoietic factors 
clearly influence angiogenesis. IL-17 is secreted by activated 
CD4 T cells and T cells [98]. IL-17 promotes angiogenesis via 
the induction of prostaglandins E1 and E2 (PGE1 and PGE2), 
VEGF, MCP-2 and NO by fibroblasts and tumor cells [99,100]. 
Moreover, IL-17 increased the secretion of angiogenic CXC 
chemokines, including CXCL1, CXCL5, CXCL6, and CXCL8 by 
tumor cell lines [101] and induced EC migration and tube 
formation via the PI3K/AKT1 pathway [102 ]. 
γδ T cells have recently gathered significant attention 
following the discovery that they produce IL-17 in various 
mouse models of infection and autoimmune disease. In 
contrast, the secretion of large amounts of IFN-gamma by γδ 
T cells has long been known, and has been tightly linked to 
their anti-tumor function. A study unexpectedly about  
lymphoid T cells that infiltrate tumor foci induced in the 
mouse skin produce very little IFN-gamma, but abundant IL-
17. In fact, these γδ T cells are the major source of IL-17 
within the tumor microenvironment, where they appear to 
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promote angiogenesis, and thus tumor growth. This 
Commentary discusses the relevance of these interesting 
findings in the context of the currently paradoxical pro- 
versus anti-tumor roles of IL-17 in cancer immunology [103], 
see figure 6. 
 
 
Figure 7 This is an illustration about the protumor 
activity of IL-17 in CRC microenvironment. Blue colored 
arrow shows cells producing IL-17. Black arrow shows 
the latter stimulated by the former. T-shaped arrow 
shows process inhibited by IL-17 and lightning arrow 
shows attack on tumor cells. 
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Figure 8 Mechanism underlying γδ T cell recognition of nonpeptide antigens and 
clinical applications 
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Figura 9 Different lineage of γδ T cells 
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Chapter 5 
Aims 
 The aims of this research were to evaluate the frequency, the 
phenotype and the effector function of prostate cancer-
infiltrating δ1 and δ2 T cells in prostatic biopsy samples and 
the correlation of these data with the presence of cancer 
versus healthy tissues and, in cancer tissues, with Gleason 
pattern. The analysis has been performed in circulating γδ T 
cells of the same patients and as control in healthy subject 
who, after transrectal echo guided prostatic biopsy, did not 
receive cancer diagnosis.  
We also studied the representation and the in vitro intra 
cellular concentration of some cytokine such as IL-17 and 
INFγ and, in particular how distributions these in the tumor 
infiltrating γδ T from 43 subjects. 
The cytokines response induced by activating Vγ9Vδ2 T cells 
using BrHPP has been also determined. 
Another aim has been to study the phenotypic 
characteristics of γδ T cell in the blood and into the core 
samples in order to evaluate whether reproducible 
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phenotypic changes in the γδ T cell compartment could be 
induced by the tumor microenvironmenent.  
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Chapter 6 
Materials and Methods 
6.1 Patients: 
We identified a consecutive series of outpatients who made 
transrectal echo guided prostatic biopsy. 
Prostate tissues, neoplastic and not, were obtained from 
Urological Department of the University Hospital of Palermo, 
from 2013 to 2015. 
Until now, we enrolled 43 patients undergoing a transrectal 
Echo guided prostatic biopsy using 16 Gauge needle. 
During the biopsy after a standard 12 core procedure was 
followed, taking two cores from the margin of right and left 
side of the prostate gland and for each patient peripheral 
blood was taken. All individuals gave written informed 
consent to participate. According to Italian rules (art. 13, 
DLgs n. 196/03), this study did not require authorisation by 
the local ethical committee. 
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After medical report we divided the individuals in three 
groups. The first group consists of 21 subject with prostate 
cancer (Mean Age 70,04 range 62 to 80; Mean PSA 10,11 
range 5,5 to 16,7); the second group consists of 4 subject 
with prostatic intraepithelial neoplasia (Mean Age 71  range 
65 to  77 Mean PSA 5,88 range 4,2  to  7,92) and the third 
groups consists of 17 healthy individual ( Mean Age 64,20 
range 43 to 80 Mean PSA 4,46 range 2,06  to 7,05). 
The principal characteristics of the patients are summarized 
in table 1 A,B,C: 
 
Table 1 A Patients with Prostate Cancer 
Number of patient Age PSA (ng/ml) Histological 
Examination 
Gleason Score 
1 66 15,05 Acinar 
adenocarcinoma  
6 (3+3) 
 
2 62 
12,33 
Acinar 
adenocarcinoma 
6 (3+3) 
 
3 78 7,86 Acinar 
adenocarcinoma 
6 (3+3) 
 
4 67 7,95 Acinar 
adenocarcinoma 
6 (3+3) 
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5 76 11 Acinar 
adenocarcinoma  
7 (3+4) 
 
6 71 13 Acinar 
adenocarcinoma 
7(3+4) 
 
7 65 10,79 Acinar 
adenocarcinoma 
8 (4+4) 
 
8 65 7,76 Acinar 
adenocarcinoma 
8 (3+5) 
 
9 80 8,79 Acinar 
adenocarcinoma 
8 (3+5) 
 
10 67 10,5 Acinar 
adenocarcinoma 
6 (3+3) 
 
11 63 5,5 Acinar 
adenocarcinoma 
6 (3+3) 
 
12 65 7,11 Acinar 
adenocarcinoma 
6 (3+3) 
 
13 69 6,43 Adenocarcinoma 6 (3+3) 
 
14 70 5,96 Acinar 
adenocarcinoma 
6 (3+3) 
 
15 78 9,02 Acinar 
adenocarcinoma 
6 (3+3) 
 
16 78 14,65 Acinar 
adenocarcinoma 
6 (3+3) 
 
17 68 6,5 Acinar 
adenocarcinoma 
7 (3+4) 
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18 73 11 Acinar 
adenocarcinoma 
7(3+4) 
 
19 70 9,98 Acinar 
adenocarcinoma 
7 (3+4) 
 
20 71 15,06 Acinar 
adenocarcinoma 
6 (3+3) 
 
21 69 16,07 Acinar 
adenocarcinoma 
6 (3+3) 
 
 
 
 
Table 1 B Patients with Prostatic Intraepithelial Neoplasia 
Number of 
patient 
Age PSA ng/ml Histological Examination 
1 65 5,01 Prostatic intraepithelial 
neoplasia Pin High Grade 
2 66 4,2 Prostatic intraepithelial 
neoplasia Pin High Grade 
3 76 7,92 Prostatic intraepithelial 
neoplasia Pin High Grade 
4 77 6,4 Prostatic intraepithelial 
neoplasia Pin High Grade 
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Table 1 C Healthy Subject 
Number of 
patients 
Age PSA ng/ml Histological Examination 
1 65 4,65 not observed sign of tumor 
lesion 
2 73 2,45 not observed sign of tumor 
lesion 
3 69 3,05 not observed sign of tumor 
lesion 
4 59 5,35 not observed sign of tumor 
lesion 
5 63 5,84 not observed sign of tumor 
lesion 
6 43 7,05 not observed sign of tumor 
lesion 
7 80 2,06 not observed sign of tumor 
lesion 
8 58 3,50 not observed sign of tumor 
lesion 
9 68 3,2 not observed sign of tumor 
lesion 
10 68 5,1 not observed sign of tumor 
lesion 
11 48 4,6 not observed sign of tumor 
lesion 
12 62 5,67 not observed sign of tumor 
lesion 
13 59 4,87 not observed sign of tumor 
lesion 
14 71 5,9 not observed sign of tumor 
lesion 
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15 67 4,03 not observed sign of tumor  
lesion 
16 65 4,6 not observed sign of tumor 
lesion 
17 72 4,5 not observed sign of tumor 
lesion 
18 66 3,9 not observed sign of tumor 
lesion 
 
 
6.2 Isolation and FACS analysis of Tumor- 
infiltrating Immune Cells (TILs) and Peripheral 
blood mononuclear cells (PBMC) 
 
Tissue was obtained fresh and immediately transported to 
the laboratory in sterile saline for processing. Tissue was first 
minced into small pieces followed by digestion with 
collagenase type IV, Hyaluronidase and DNAase (Sigma, St. 
Louis, MO) for one hour at 37°C. After digestion, the cells 
extracted was washed twice in RPMI 1640 medium. 
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Whole blood samples were obtained from the same patients 
recruited for the collection of tissue specimens and used for 
the comparative analysis between immunological status in 
peripheral blood and in the cancer or inflamed tissue. The 
peripheral blood mononuclear cells (PBMCs) were separated 
from whole blood by density gradient centrifugation using 
Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). PBMC 
were used for the staining with the same mAbs used for the 
study of the TILs, acquired and analyzed by flow cytometry 
on an FACSCalibur. 
The fluorescein isothiocyanate (FITC)-, phycoerythrin (PE)-
,PE-Cy5- or allophycocyanin (APC)- conjugated monoclonal 
antibodies (mAbs) used to characterized the entire 
population and cytokine were the following: anti-CD3, anti-
Vδ1, anti-Vδ2, anti-CD27 and anti-CD45RA, anti IFNγ and anti 
IL17 all purchased from BD Biosciences (Mountain View, CA). 
Expression of surface markers was determined by flow 
cytometry on an FACSCalibur. Flow cytometry analysis was 
used to identify and characterize the γδ T cell populations 
and IL 17 and IFNγ using the following conjugated 
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monoclonal antibodies (mAbs): anti-Vδ1FITC, anti-Vδ2PE, 
anti-CD27APC and anti-CD45RA PECy5, antiCD3, anti-Il 17 
PerCp/Cy5.5 and anti-IFNγ APC. 
The gating strategy involved progressively measuring total 
cells; viable cells only; lymphomonocytes and specific cell 
types. For every sample 100.000 nucleated cells were 
acquired and values are expressed as percentage of viable 
lymphomonocytes, as gated by forward and side scatter. 
 
6.3. Stimulation of  γδ T cells in vitro and Cytokine   
Production 
 
Purified  γδ T cells (500000/1000 μl) were cultured in 24-well 
round-bottom plates,in complete RPMI medium with 10% 
Fetal Bovin Serum in absence or presence of 10 μg/ml of 
BrHPP;1μg/ml of Ionomicina and 15 μg PMA for 1 h, at 37°C 
in 5% CO2. 
73 
 
The cytokine production capacity of Vδ1 and Vδ2 T cell 
derived both cancer tissues and healthy tissues were 
determined after stimulation with PMA (BD Biosciences, 15 
μg /ml) and ionomycin (BD Biosciences, 1 mM) and 10 μg/ml 
of BrHPP for 1 hrs at a cell concentration of 500000/ml.  
For the intracellular staining for IFN-γ and IL-17, we taken the 
TILs and we stimulated in the presence of monensin for 3 h 
at 37°C in 5% CO2 were harvested, washed, and stained with 
anti-Vδ2 and anti-Vδ1 mAbs in incubation buffer (PBS 
containing 1% FCS and 0.1% Na azide) for 30 min at 4°C. 
Cells were then washed twice in PBS with 1% FCS and fixed 
with PBS containing 4% paraformaldehyde overnight at 4°C. 
Fixation was followed by permeabilization with PBS 
containing 1% FCS, 0.3% saponin, and 0.1% Na azide for 15 
min at 4°C, and fixed permeabilized cells were stained with 
an anti–IFN-γ and IL-17 antibodies. After two more washes in 
PBS containing 1% FCS, the cells were analyzed by 
FACSCalibur. Lymphocytes were gated by forward and side 
scatter and analysis done on 100,000 acquired events for 
each sample. The detection of IFNγ and IL17 were obtained 
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from the following conjugated monoclonal antibodies 
(mAbs): anti-Il 17 PerCp/Cy5.5 and anti-IFNγ APC, BD 
Pharmingen and performed according to the manufacturer’s 
instructions.  
 
6.4 Statistical analysis  
Statistical significance of obtained results were evaluated by 
(T-StudenT) (p≤0.05). All experiments were performed at 
least three times and representative cytograms are 
presented. 
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Chapter 7 
7.1 Results  
The γδ T cells analysis, performed on prostatic samples using 
common bioptic technique, has been always feasible.    
The γδ T cells present in the prostatic tissue disclose wide 
variability in all the samples and in the samples of the three 
groups: healthy, prostatic cancer and prostatic intraepithelial 
neoplasia. 
γδ T cells variability has been also observed in PBMC 
samples. 
 The Percentage of Vδ1 and Vδ2 T cells in PBMCs from 
healthy and prostatic cancer is showed in the figure 10. As 
shown in the figure the percentage of δ2 T cells was higher 
in PBMC of cancer patients while δ1 T cells in PBMC of 
healthy patients. Number of enrolled patients = 39 (21 with 
cancer,18 healthy), these data were statistically significance 
(P< 0,05). When we compared Vδ2 T cells from cancer 
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patients and healthy subject the data were a statistically 
significant  P<0,05. 
The percentage of infiltrating γδT cells in the cores prostatic 
from patients with prostate cancer, prostatic intraepithelial 
neoplasia and healthy tissue is displayed in the figure 11.  
Both δ1 and δ2 T cells are more expressed in prostate cancer  
patients, respectively 6,15 % and 8,49 % than in tissues with 
PIN, 2  % and 5,98 %. and healthy patients 5,71 %, and 5,23 %  
P >0,05. The percentage of tumor-infiltrating γδT cells in 
adenocarcinoma in according to Gleason score is showed in 
the figure 12. This figure shows the association between the 
rate of γδ T cells and the clinical features in patients with 
prostate cancer and grading according to Gleason 
classification. The distribution of infiltrating δ2 T cell in the 
cancer with Gleason pattern 4-5 decreases than pattern with 
Gleason 3. Cancers with a higher Gleason score are more 
aggressive and have a worse prognosis. The data showed  
that more aggressive tumors have a lower percentage of 
Vδ2 and Vδ1 T cells, these results were statistically significant 
P<0,05 for Vδ2 T subset. 
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To understand the phenotypes of the tumor-infiltrating 
Vδ2+T cells was due to the tumor microenvironment or 
simply reflected an overall bias in prostate cancer patients, 
we studied the phenotype of γδ T cells in the peripheral 
blood and tissue as shown in Figure 13A and 13B. Vδ2+T 
cells obtained from peripheral blood of cancer subjects 
showed a predominant TCM phenotype (38,51%) P<0,05. 
While a different pattern was found for Vδ2+ γδ T cells in the 
prostate cancer-infiltrating where the dominant phenotype 
(40,28 %.)  was the TEM phenotype P<0,05. These results 
clearly demonstrate that the cells committed to effector 
activities at the tumor site are phenotypically different 
respect to circulating Vδ2 T cell.   
The phenotype of the Vδ1 T cells in PBMCs of patients with 
prostate cancer and healthy individuals and in the 
infiltrating Vδ1 T cells of healthy tissues and cancer tissues, is 
showed in figure 14 A-B. The most prevalent phenotype in 
PBMCs δ1 T cells of patients with prostate cancer was TEMRA 
(40.73%.) P>0,05 while the most  prevalent phenotype in 
TILS was TEM phenotype (38.31%) P<0,05. The most 
prevalent phenotype in PBMCs of healthy subject was 
TNaive.  
The data, produced so far, show that in the patients with 
prostate cancer the main subset infiltrating lymphocyte is 
represented by Vδ2 T-Cells had a phenotype TEM. Human γδ 
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T cells include those with naive or central-memory 
phenotypes that home to secondary lymphoid organs, but 
that lack immediate effect function, and those with effector-
memory and terminally-differentiated phenotypes that 
home to sites of inflammation and that display immediate 
effector functions as cytokine production and cytotoxic 
activity.  
The majority of tumor-infiltrating Vδ2 T cells shows a TEM 
phenotype, indicative for cells that home to sites of 
inflammation and that display immediate effector functions 
as cytokine production or cytotoxic activity.  
The percentages of Vδ1   and Vδ2 T cells expressing 
intracellular cytokines IL17 and IFNγ from TILS derivate from 
Prostate cancer  tissues and healthy  is showed in figure 15 -
16 -17.   The flow cytometry quantitative assay shows an 
amount of IL17 and IFN γ in the control sample (RPMI). Vδ1   
and Vδ2 T cells IFN γ positive were higher in prostate cancer 
tissues than in healthy tissues. After stimulation with 
Ionomycina and BrHpp the samples induced an increase of 
IFN γ in healthy tissues but were not able to induce an 
increase of IFN γ in cancer tissues, these data were 
statistically significance for Vδ2 T cells and not significance 
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for Vδ1 T cells P<0,05 (when we used Ionomycin the P was 
0,0456  and P was 0,0364 when we stimulated with BrHpp).  
The percentage of cytokine IL-17 in cancer tissues did not 
show an increase after Ionomycin togheter PMA and BrHpp 
stimulation in both Vδ1 and Vδ2 T cells. Only Vδ2 T cells in 
healthy tissues showed an increase of cytokine IL-17 
percentage after Ionomycin and BrHpp stimulation, the 
results were statistically significance P<0,005. 
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Chapter 8 
8.1 Discussion 
Substantial evidence indicates that the immune system 
participates in tumorigenesis  and may contribute to either 
disease progression or inhibition of tumor growth, for  
decrease tumor lesion to be markedly infiltrated by 
mononuclear cells and the presence of γδT cells has been 
associated with improved prognosis in patients with 
different types of carcinoma [70]. 
Given that γδ cells mediate antigen-specific killing of tumor 
cells, we studied their distribution and the intracellular 
cytokine expression in tumor infiltrating γδ T cells from  
patients with prostate cancer and healthy subject. We found 
that γδ cells are largely present in infiltrating prostate 
cancer, and both Vγ1 + and Vγ2+ cells are involved. 
The majority of adenocarcinoma prostatic infiltrating γδ cells 
showed effector memory and terminally-differentiated 
phenotypes and, accordingly γδT obtained from tumor-
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infiltrating immune cells produced IFN γ and IL17. Our study 
showed the presence of higher rate of γδT isolation, 
particularly Vδ2 T cells than healthy tissue in prostate cancer 
with Gleason Pattern 3, while a decrease in prostate cancer 
with  Gleason Pattern 4 and 5.  
Given that Vγ2+ T cells are absent from normal skin [88], 
their presence in the context of prostate cancer is highly 
suggestive of a migratory process from the blood or 
lymphoid tissues. Accordingly, the majority of prostate 
cancer-infiltrating Vγ2+ T cells have a TEM and TEMRA 
phenotype, characteristic for cells that home to sites of 
inflammation and that display immediate effector function 
as cytokine production. Conversely, circulating Vγ2+ T from 
the same patients have a predominant TCM phenotype, 
similarly to that occurring in healthy subjects, and that 
identifies cells that home to secondary lymphoid organs, but 
that lack immediate effector function. 
Specific γδ T-cell subsets are capable of recruiting 
immunosuppressive myeloid populations, inhibiting 
antitumor responses, and enhancing angiogenesis, thus 
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promoting cancer progression. A common mediator of such 
functions appears to be the cytokine IL17, whose pathogenic 
effects can override the antitumor immune response 
orchestrated by IFNγ  [2].  
These results strongly indicate that while Vγ1+ T cells may 
be activated locally in the tumor microenvironment, Vγ2+ T 
are recruited from the blood or secondary lymphoid organs 
by virtue of a migratory process orchestrated by cytokines.  
Altogether, our results suggest that a natural immune 
response mediated by γδ T lymphocytes may contribute to 
the immunosurveillance of prostate cancer. 
The localization of γδ T cells, as Vδ2 T cells, within epithelia 
suggests that these cells may contribute to the surveillance 
of malignancies, including prostate cancer.   Vδ1 T cells are 
the prevalent γδT cells population in human tissues 
including intestinal epithelium and skin [88]. 
Vδ2 T cells are absent in normal skin and their presence in 
the context of prostate cancer, more than in healthy 
prostate tissue, as we have observed in our study,   is highly 
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suggestive of a migratory process from the blood or 
lymphoid tissues . 
IL-17 expression is elevated in several human tumors, such 
as ovarian, cervical cancer, breast cancer, hepatocellular 
carcinoma, esophageal cancer, gastric cancer and colorectal 
cancer [103] and accumulative evidence reveals that IL-17 
can promote tumor initiation and progression in most 
cancer but the exact mechanism of IL17 in tumor initiation 
and progression is not yet clear. Some researchers propose 
that IL 17 promotes tumor initiation and progression 
through suppressing antitumor immune response. 
Thus, some attempts for cancer immunotherapy targeting 
IL-17, such as neutralizing antibody, and approaches or 
decreasing IL-17 production or blocking the downstream 
signaling pathways would come true with the deepening of 
IL-17 related research in the future. In our study we observed 
that IL-17 γδT cells both Vδ1 and Vδ2, enhanced after 
Ionomycin and BrHpp stimulation only in healthy tissues but 
not in prostate cancer tissues. 
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IFNγ positive Vδ1 and  Vδ2 T cells are probably those more 
implicated in the immunosurveillance against tumour and 
we observed an increase of IFNγ positive Vδ2 T cells in 
prostate cancer tissues that did not show an increase after 
Ionomycin and BrHpp stimulation.  
The analysis of IFNγ positive Vδ2 T cells in prostate cancer 
tissue could have a clinical prognostic significance and could 
guide the different therapeutic options, for example active 
surveillance versus radical prostatectomy. A prostate cancer 
with abundant IFNγ positive Vδ2 T cells could be a sign of a 
more favourable prognosis in add to the other known 
prognostic information like Gleason score and clinical stage. 
This is particularly important because this analysis is feasible 
in prostate tissues derived by prostatic biopsy, as we showed 
in our study. 
 Although great progress has been made in γδ T cell-based 
immunothearpies, many aspects need to be improved in 
future clinical trials. 
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The identification of biomarkers to predict clinical outcome 
is crucial for patient selection. A recent study, for example, 
has identified a panel of 10 genes which encode cell surface 
proteins that segregated ''γδ-susceptible'' from ''γδ-
resistant'' hematologic tumors [104]. Equivalent markers 
could be promptly characterized in multiple cancer types, 
and their predictive value should be accessed in γδ T cell-
based clinical trials. The combination of ''susceptible'' tumor 
profiles with improved strategies for γδ T -cell activation in 
vivo may be the way forward for γδ T cell-based cancer 
immunotherapy. γδ T cells are attractive targets for cellular 
immunotherapy, but protocols for their therapeutic use 
need to be optimized. In addition, it is necessary to explore 
better antigens which help us stimulate γδ T cell expansion 
in vitro for the preparation of a large number of cells for 
adoptive cell transfer. Future studies should focus on the 
possible advantages of combining γδ T cell–based 
immunotherapy with conventional chemotherapy or other 
therapeutic approaches, such as antiangiogenic drugs. 
Future trials should harness biphosphonate activated γδ T 
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cells in combination with chemotherapy or monoclonal 
antibodies for treatment of solid tumors and haematolic 
malignancies. 
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Chapter 9 
Graphics 
 
 
Figura 10 Percentage of Vδ1 and Vδ2 T cells in PBMCs of healthy 
patients and PBMCs of prostate cancer PCa and percentage of Vδ1 
and Vδ2 T cells in TILS-PCa and Healthy tissue. Number of enrolled 
patients = 39 (21 with cancer, 18 Healthy subject) . (P=0,0048 DS δ1 
1,62 DS δ2 =0,91)  P=0,0457 DS δ healthy 1,29 δ2 cancer DS 1,96 ) 
P=0,0006 DS δ21,96 DSδ1 0,34 
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Figura 11 Percentage of Vδ1 and Vδ2 T cells in TILS, in prostatic 
intraepithelial neoplasia (PIN) tissue and healthy tissue. Number of 
enrolled patients = 43 (21 with cancer, 18 with healthy , 4 with PIN) 
(P>0,05). 
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Figure 12 Percentage of Vδ2 and Vδ1 T cells in TILs from patients with 
prostatic cancer with Gleason pattern 3 and 4-5. Total patients 21 (13 patients 
of them have a Gleason score with pattern 3 and 8 of them have a pattern 4-5) 
(P<0,03  Vδ2 T in relation to Gleason score pattern 3 and score 4-5). The 
subset Vδ1 was  P>0,05 Gleason 3 correlation with pattern 4-5. DS gleason 
3 δ2=7,97 DS gleason 4-5 δ2=2,80 
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Figura 13 A- Comparision of Vδ2 T cells subset in PBMCs form patients with 
prostate cancer and healthy individuals. PBMCs from patients with cancer 
PBMC-PCa and healthy subjects were obtained as described under Materials 
and Methods and were stained with anti-Vδ2 T, anti-CD45RA and CD27 mAbs. 
Percentage of TNaive (CD45RA+ CD27+)TCM( CD45-CD27+) TEM (CD45RA- CD27) 
were obtained by FACS analysis. DS TN=17,29 DS TEM=33,63 
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Figura 13 B- Comparision of Vδ2 T cells subset in TILS form patients 
with prostate cancer and healthy individuals. TILS from patients with 
cancer PCa and healthy tissue were obtained as described under 
Materials and Methods and were stained with anti-Vδ2 T, anti-
CD45RA and CD27 mAbs. Percentage of TNaive (CD45RA+ CD27+)TCM( 
CD45-CD27+) TEM (CD45RA- CD27) were obtained by FACS analysis. 
The Phenotype distribution of the infiltrating Vδ2 T cells in healthy 
tissues and cancer tissues the P<0,0150 in cancer tissues TN-TCM and 
TN-TEM). DS TN 16,91 DS TCM 30,53) TN DS 17,29 TEM DS 33,63 
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Figura 14 A- Comparision of Vδ1 T cells subset in PBMCs form 
patients with prostate cancer and healthy individuals. PBMCs from 
patients with cancer PBMC-PCa and healthy subjects were obtained 
as described under Materials and Methods and were stained with 
anti-Vδ2 T, anti-CD45RA and CD27 mAbs. Percentage of TNaive 
(CD45RA+ CD27+)TCM( CD45-CD27+) TEM (CD45RA- CD27) were obtained 
by FACS analysis. P>0,05 
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Figura 14 B- Comparision of Vδ1 T cells subset in PBMCs form 
patients with prostate cancer and healthy individuals. PBMCs from 
patients with cancer PBMC-PCa and healthy subjects were obtained 
as described under Materials and Methods and were stained with 
anti-Vδ2 T, anti-CD45RA and CD27 mAbs. Percentage of TNaive 
(CD45RA+ CD27+)TCM( CD45-CD27+) TEM (CD45RA- CD27) were obtained 
by FACS analysis. The Phenotype distribution of the infiltrating Vδ1 T 
cells in healthy tissues and cancer tissues the was P=0,0000 in cancer 
tissues TN- TEM). TN DS 9,78 TEM 35,94 
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Figura 15 Cytokine production capacity of Prostate cancer PCa-
derived γδ T cells TILS and Healthy Tissue. Cytokine production by 
Vδ1 T  from cancer and healthy tissue were determined by FACS 
analysis of supernatants with only RPMI ( negative control without 
stimulation)  and after 4 hrs stimulation with PMA and ionomycin 
(Positive control) and stimulation with BrHpp ( Antigen Specific 
Control ) . P>0,05 
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Figura 16 Percentages of Cytokines Vδ2 T from CaP and Healthy 
tissues.  Cytokine production capacity of Prostate cancer PCa-derived 
γδ T cells TILS and Healthy Tissue. Cytokine production by Vδ2 T  from 
cancer and healthy tissue were determined by FACS analysis of 
supernatants with only RPMI ( negative control without stimulation)  
and after 4 hrs stimulation with PMA and ionomycin (Positive 
control) and stimulation with BrHpp ( Antigen Specific Control ) . 
P>0,05 
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Figura 17 Cytokine production capacity of Prostate cancer PCa-
derived γδ T cells TILS. Cytokine production by Vδ2 T from TILS were 
determined by FACS analysis of supernatants with only RPMI ( 
negative control without stimulation)  and after 4 hrs stimulation 
with PMA and ionomycin (Positive control) and stimulation with 
BrHpp ( Antigen Specific Control ) . P<0,05 DS 6,36 DS 2,27 
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